Travoprost (Travatan)

Travoprost (brand name Travatan, Travatan Z) is a prostaglandin analog eye drop used to lower intraocular pressure in open-angle glaucoma and ocular hypertension. Like the rest of its class - latanoprost, bimatoprost, and tafluprost - it provides among the strongest single-drop pressure reductions available, with a once-daily dose. The class side effects (gradual iris darkening, lash growth, periocular pigmentation) are shared with the other prostaglandin analogs.

How It Works

Travoprost is a synthetic analog of prostaglandin F2α. It binds to FP receptors and increases the outflow of aqueous humor, primarily through the uveoscleral pathway with smaller effects on the trabecular meshwork - the opposite mechanism from timolol (which reduces production). Increased outflow lowers eye pressure significantly without changing pupil size, accommodation, or aqueous production.

The effect:

• Begins within 2 hours of dosing
• Reaches peak at 12 hours
• Lasts 24+ hours, supporting once-daily dosing

Common Uses

• Primary open-angle glaucoma
• Ocular hypertension
• Normal-tension glaucoma
• Adjunctive therapy with other classes

Combinations:

• DuoTrav - travoprost + timolol (available in Europe and other markets; not FDA-approved in the U.S.)
• In the U.S., travoprost is typically combined with other classes as separate drops rather than as a travoprost fixed-combination product

How to Use

• Dosing: One drop in the affected eye(s) once daily, in the evening
• Evening dosing matches the typical diurnal IOP rhythm and gives slightly better 24-hour pressure control than morning dosing
• Press on the inner corner of the eye for 1-2 minutes after instillation
• Wait 5+ minutes between different eye drops
• Remove contact lenses before use; reinsert after 15 minutes
• More than once daily does not produce additional pressure lowering and may paradoxically reduce effect

What to Expect

Pressure Reduction

• Typically about 25-33% IOP reduction - comparable to other prostaglandin analogs
• Effect builds over the first few weeks
• Steady-state reached in 1 month

Local Effects

• Mild conjunctival hyperemia (red eye) is common, particularly in the first weeks; often improves
• Eyelash growth - longer, thicker, darker lashes within 4-6 weeks. The change persists while the drop is used and partially reverses over months after stopping.
• Iris color darkening - slow change, typically over 6-12 months, in patients with mixed-color irises (hazel, green-brown). Usually permanent. Less commonly affects pure blue or pure brown irises.
• Periocular and eyelid skin darkening - gradually develops with chronic use; usually fades partially or fully after stopping, but may not always reverse completely
• Periocular fat atrophy (prostaglandin-associated periorbitopathy) - subtle hollowing of the upper eyelid sulcus. May improve after discontinuation or switching.
• Cystoid macular edema - uncommon; reported particularly in pseudophakic eyes (after cataract surgery), especially with disrupted posterior capsule
• Reactivation of herpes simplex keratitis in patients with prior history

Systemic Effects

• Much less systemic activity than timolol
• Rare reports of mild upper respiratory symptoms or muscle aches
• No significant impact on heart rate, blood pressure, or breathing in most patients

Precautions

Prior Herpes Simplex Keratitis

Prostaglandin analogs may reactivate herpetic keratitis. Use cautiously and consider antiviral coverage if needed.

Active Uveitis or Cystoid Macular Edema

Avoid in active inflammation; can worsen.

Pseudophakic Eyes with Disrupted Posterior Capsule

Higher risk of cystoid macular edema; weigh benefit against risk.

Pregnancy and Breastfeeding

Travoprost in animal studies showed embryofetal toxicity and uterine effects at systemic exposures higher than ophthalmic dosing. It is generally avoided during pregnancy when clinically feasible - alternative agents (such as a beta-blocker with punctal occlusion) are usually preferred, particularly during the third trimester. Discuss with your obstetrician and ophthalmologist.

Travoprost vs. Other Prostaglandin Analogs

Most patients respond similarly to all prostaglandins. Choice often comes down to formulation tolerance, insurance coverage, and individual response.

Travatan Z (BAK-Free Formulation)

Branded Travatan Z uses an ionic-buffered preservative system (SofZia) instead of benzalkonium chloride; branded and generic availability can change. Generic travoprost 0.004% products are also available - some are BAK-preserved and some use alternative preservative systems, so check the label of the specific product dispensed. The BAK-free formulation may be tolerated better in patients with ocular surface disease or dry eye.

Frequently Asked Questions

Will my eye color really change?

Iris darkening is a recognized class effect of prostaglandin analogs and occurs over 6-12 months in some patients, particularly those with mixed-color irises. The change is typically gradual and is usually permanent - even after stopping the drop, the new pigment does not reverse. Patients with pure blue or pure brown eyes are less likely to notice a change.

Why do my eyelashes grow longer?

Prostaglandins stimulate hair follicle growth. The same mechanism is the basis for the cosmetic eyelash drug bimatoprost (Latisse), which is the same molecule as the glaucoma drop applied to the lash line. Lash growth is common with chronic prostaglandin use; if treatment is one-sided, the asymmetry can be cosmetically noticeable.

Why is travoprost dosed at night?

Once-daily evening dosing matches the typical eye pressure rhythm - pressure tends to be highest at night and early morning - and produces slightly better 24-hour pressure control than morning dosing.

What if I miss a dose?

Take it as soon as you remember if it is still that day; if you are nearly at the next scheduled dose, skip the missed one. Do not double up. Missing one dose is not catastrophic but consistent missed doses leave the eye unprotected.

Are prostaglandin analogs safe long-term?

Yes, in general. They have been in clinical use since the 1990s with extensive safety data. The most relevant long-term concerns are the cosmetic effects (iris pigmentation, periocular changes), and rare reports of macular edema in selected eyes. Systemic side effects are much less common than with beta-blocker drops.

Can I switch from latanoprost to travoprost?

Yes - they are different molecules in the same class, and some patients respond better to one than the other, although direct head-to-head differences are usually small. Switching is straightforward; the effect of the new drop reaches steady-state within a few weeks.